前往化源商城

17606-31-4 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3083044
Protocol: N/A
Comment: Journal: J Pesticide Sci
Year: 2009
Volume: 34
Issue: 1
First Page: 13
Last Page: 20
DOI: 10.1584/jpestics.G08-26
Standard TypeStandard RelationStandard Value
Ratio EC50=-0.58
Ratio EC50=3.09
Ratio EC50=0.15
Ratio EC50=-0.75
Ratio EC50=-0.77
Ratio EC50=0.04
Ratio EC50=-0.31
Ratio EC50=0.47
Ratio EC50=4.43
Ratio EC50=4.31
Ratio EC50=3.35
Ratio EC50=4.17
Ratio EC50=3.63
Ratio EC50=0.3
Ratio EC50=-0.26
Ratio EC50=0.69
Ratio EC50=0.39
Ratio EC50=1.24
Ratio EC50=0.17
Ratio EC50=2.54
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cheumatopsyche
External ID: CHEMBL3083045
Protocol: N/A
Comment: Journal: J Pesticide Sci
Year: 2009
Volume: 34
Issue: 1
First Page: 13
Last Page: 20
DOI: 10.1584/jpestics.G08-26

Target ChEMBL ID: CHEMBL2366796
ChEMBL Target Name: Cheumatopsyche
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
EC50=0.0214ug.mL-1
EC50=1.53E-4ug.mL-1
EC50=0.00778ug.mL-1
EC50=0.00202ug.mL-1
EC50=0.00117ug.mL-1
EC50=0.00948ug.mL-1
EC50=0.00177ug.mL-1
EC50>0.83ug.mL-1
EC50=2.05E-4ug.mL-1
EC50=0.00444ug.mL-1
EC50=0.00422ug.mL-1
EC50=0.045ug.mL-1
EC50=0.00335ug.mL-1
EC50=0.00527ug.mL-1
EC50=6.0E-4ug.mL-1
EC50=0.00181ug.mL-1
EC50=1.16E-4ug.mL-1
EC50=0.00214ug.mL-1
EC50=0.0037ug.mL-1
EC50=0.00666ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL3083046
Protocol: N/A
Comment: Journal: J Pesticide Sci
Year: 2009
Volume: 34
Issue: 1
First Page: 13
Last Page: 20
DOI: 10.1584/jpestics.G08-26
Standard TypeStandard RelationStandard Value
log KOW=1.85
log KOW=4
log KOW=3.43
log KOW=0.43
log KOW=1.9
log KOW=2.79
log KOW=3.3
log KOW=4.25
log KOW=6.1
log KOW=0.7
log KOW=0.57
log KOW=-0.66
log KOW=0.8
log KOW=1.26
log KOW=8.2
log KOW=2.75
log KOW=7.05
log KOW=4.84
log KOW=4.22
log KOW=-0.07
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: LDHA
Protocol: The assay was optimized to 1536-well plates. Briefly, 3 muL of human lactate dehydrogenase 5 (#A38558H, Meridian Life Science, Inc., Memphis, TN) in LDH assay buffer (200 mM Tris HCl pH 7.4, 100 microM EDTA and 0.01% Tween-20) was added to a black solid bottom 1536-well assay plate (Greiner Bio-One) using a BioRAPTR FRD dispenser (Beckman Coulter, Brea, CA). A 1536-well pintool dispenser outfitted with 20 nL pins (Wako Automation, San Diego, CA) was used to transfer 23 nL of DMSO-solubilized compound (both library and vehicle controls) to each 1536-well assay plate. Following compound transfer, 1 muL of substrate solution containing NADH and sodium pyruvate (Sigma-Aldrich, St. Louis, MO) in LDH assay buffer was dispensed via BioRAPTR FRD to initiate the reaction. Final concentrations in the 4 microL reaction volume were 2 nM LDHA enzyme, 0.06 mM NADH and 0.2 mM sodium pyruvate. Following a 5 minute incubation period at room temperature, 1 muL of detection reagent (C. kluyveri diaphorase (Sigma-Aldrich) and resazurin sodium salt (Sigma-Aldrich) in LDH assay buffer) was added to a total volume of 5 muL. Final concentrations of detection reagents were 0.133 mg/mL diaphorase and 37 muM resazurin. Plates were immediately transferred to a ViewLux microplate imager (PerkinElmer, Waltham, MA), and any resulting resorufin fluorescence was measured (ex540, em590 nm) at 0 and 20 minutes. Fluorescence was normalized using enzyme-free and DMSO-treated control wells on each plate.
Comment: PubChem score indicates % inhibition at 229 uM or 114 uM of the compound (Max_response). Active compounds with Max_response greater than -100%, PUBCHEM_ACTIVITY_SCORE is 100. Active compounds with Max_response between -80% and -100%, PUBCHEM_ACTIVITY_SCORE is 80. Active compounds with Max_response between -60% and -80%, PUBCHEM_ACTIVITY_SCORE is 60. Active compounds with Max_response between -30% and -60%, PUBCHEM_ACTIVITY_SCORE is 40. Inconclusive Compounds with Max_response between -25% and -30% have PUBCHEM_ACTIVITY_SCORE 20. For all inactive compounds with Max_response greater than -25%, PUBCHEM_ACTIVITY_SCORE is 0
Max_ResponseActivity at 2.29 uMActivity at 11.40 uMActivity at 57.10 uMActivity at 114.0 uMActivity at 229.0 uMCompound QC
-13.2744-14.0597-11.6112-13.2744QC'd by CBC
-13.2736-2.2436-1.4106-3.5076-4.2706-13.2736QC'd by ChemBridge
-13.2725-6.3492-3.253-0.0584-6.7999-13.2725QC'd by Enamine
-13.2721-2.684-6.1454-14.2744-13.2721-0.8973QC'd by InterBioScreen
-13.26881.98380.4889-13.2688QC'd by CBC
-13.2682-4.48462.9589-5.115-5.7595-13.2682QC'd by Sytravon
-13.2658-0.93-4.4888-3.7077-0.7595-13.2658QC'd by Scripps Research Institute Molecular Screening Center-Florida
-13.2621-10.0397-8.5786-8.5671-13.2621-10.4851QC'd by InterBioScreen
-13.2619-4.902-18.7355-13.2619QC'd by CBC
-13.2616-5.6993-9.4488-8.2485-1.1117-13.2616QC'd by Asinex Ltd.
-13.2589-2.6923-5.6679-1.3754-4.9233-13.2589QC'd by ChemBridge
-13.2586-7.6996-6.7417-9.0608-13.258613.0861QC'd by Chem Div
-13.2584.5885-10.8854-13.258QC'd by CBC
-13.2566-1.7741-2.7236-3.5771-3.8709-13.2566QC'd by Chem Div
-13.255-2.1061.9951-5.3796-7.5294-13.255QC'd by Sytravon
-13.2542-3.8713-0.3776-5.8085-5.7762-13.2542QC'd by Sytravon
-13.2537-9.0401-8.2673-9.7055-13.2537QC'd by ChemBridge
-13.2524-8.3625-5.9151-4.3599-2.4204-13.2524QC'd by Life Chemicals
-13.2524-11.5667-8.9808-13.1831-13.2524-13.0056QC'd by Enamine
-13.252412.60356.6367-13.2524QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Chilo suppressalis
External ID: CHEMBL3058006
Protocol: N/A
Comment: Journal: Biosci. Biotechnol. Biochem.
Year: 1992
Volume: 56
Issue: 10
First Page: 1623
Last Page: 1631
DOI: 10.1271/bbb.56.1623

Target ChEMBL ID: CHEMBL2366663
ChEMBL Target Name: Chilo suppressalis
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard Units
LD50=2.3mg.kg-1
LD50=1.7mg.kg-1
LD50=3.7mg.kg-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Daphnia magna
External ID: CHEMBL3083048
Protocol: N/A
Comment: Journal: J Pesticide Sci
Year: 2009
Volume: 34
Issue: 1
First Page: 13
Last Page: 20
DOI: 10.1584/jpestics.G08-26

Target ChEMBL ID: CHEMBL2367202
ChEMBL Target Name: Daphnia magna
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
EC50=0.0056ug.mL-1
EC50=0.19ug.mL-1
EC50=0.011ug.mL-1
EC50=3.6E-4ug.mL-1
EC50=2.0E-4ug.mL-1
EC50=8.7E-4ug.mL-1
EC50=3.8ug.mL-1
EC50=6.0E-4ug.mL-1
EC50>119ug.mL-1Outside typical range
EC50=85.2ug.mL-1Outside typical range
EC50>100ug.mL-1Outside typical range
EC50=50ug.mL-1
EC50=22.52ug.mL-1
EC50=0.0012ug.mL-1
EC50=0.001ug.mL-1
EC50=5.7E-4ug.mL-1
EC50=0.0052ug.mL-1
EC50=0.065ug.mL-1
EC50=0.0099ug.mL-1
EC50=0.0088ug.mL-1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:Center for Chemical Genomics, University of Michigan 靶标:
External ID: MScreen:TargetID_600
Protocol: C-terminally 6xHis tagged CDK2/Cyclin A complex and N-terminally Flag tagged CDC25B C473S (372-566) were expressed and purified. Proteins were incubated together at a final concentration of 125 nM each for 1 hr prior to incubation with compound for 1 hr, followed by addition of anti-6xHis europium cryptate donor beads (Cisbio) and anti-Flag XL-665 acceptor beads (Cisbio) at a final dilution of 1:350 for 1 hr. 20mM potassium fluoride was added 10 minute prior to plate reading. Assay reagents were dispensed using a multidrop liquid dispenser (Thermo Scientific) onto uncoated, black, low-volume, 384-well plates (Corning). Assay plates were quantified using an Envision plate reader (Perkin-Elmer) with excitation of the europium crytate donor at 337 nm wavelength and emission of the donor at 620 nm and emission of the XL-665 acceptor at 665 nm in 18 uL volumes. Assays were performed in a buffer containing 50 mM Tris (pH 7.5), 50 mM NaCl, 10mM MgCl2, 1mM TCEP, with addition of and 1mM ATP, 0.05% BSA, and 0.05% Tween-20 immediately prior to the start of the assay.
Comment: The activity outcome is based on a Z-score (number of standard deviations from the negative control mean) of 3 or higher on at least 50% times that the sample was screened.
For instance, if the sample was screened in n=4 runs, it would be considered active only if it had a Z-score of 3 or above in at least 2 runs.

This screen was funded by NIH grant number: R01CA181185
Z_SCORE
0.28
-0.54
-0.02
0.22
0.37
-0.81
-0.26
-0.14
-0.61
-0.44
0.29
0.22
-0.12
-0.13
0.95
-0.29
-0.37
0.17
-0.64
-0.78
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: stopgo-p2-SytraCBC-dual-FF
Protocol: Reagents:
StopGo2A HEK-NPG-Luc cells and other necessary media and controls were provided by Dr. Atkins's lab. Compound PTC124 was used as a control. Dose response was assessed using a 1:2 dilution of control compound, with the top dose of 50uM final concentration. Background signal was normalized to wells treated with DMSO only.

Assay Protocol:
In brief, four microliters (2400 cells/well) of StopGo2A HEK-NPG-Luc cells were plated and incubated overnight at 37C. Twenty-three nanoliters of compounds and control were added to the wells using a 1536 array Kalypsys pintool workstation. After an over night incubation (at 37C) with compounds / control, 2.5 uL of Dual/Glo Firefly reagent was added. Firefly luciferase signal was obtained using the PerkinElmer ViewLux plate reader after 20min of room temperature incubation. Dual/Glo Renilla Lucifrase reagents were then added followed by additional 20 min room temperature incubation. Finally, the renilla luciferase signal was obtained using the PerkinElmer ViewLux reader.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00460 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.112 uMActivity at 0.230 uMActivity at 0.460 uMActivity at 0.871 uMActivity at 0.984 uMActivity at 1.439 uMActivity at 2.300 uMActivity at 4.560 uMActivity at 5.230 uMActivity at 7.193 uMActivity at 11.50 uMActivity at 22.87 uMActivity at 26.96 uMActivity at 44.22 uMActivity at 57.50 uMActivity at 114.7 uMActivity at 121.0 uMCompound QC
Inactive0-6.84.95490.81592-8.87640 0 0 0-0.3922-6.984.92071.8774-0.3922QC'd by CBC
Inactive0-64.95490.99893-8.474340 0 0 1-8.9436-8.7286-0.74863.1076-8.9436QC'd by CBC
Inactive0-5.451.75290.999931.5-1.401840 0 0 10-1.16822.48627.83070QC'd by CBC
Inactive0-60.60.9574-3.55781840 0 0 0-2.964813.96745.37522.1822-2.9648QC'd by CBC
Activator0.891355.35450Complete curve; partial efficacy; poor fit-6.054.95490.996847.9876-7.36691.40 0 0 045.9161-7.516336.245149.430745.9161QC'd by CBC
Inactive04-0.40613.15817.14891.8466-0.4061QC'd by CBC
Inactive048.02199.75862.63914.5158.0219QC'd by CBC
Inactive0-4.72.90230.933614-3.767840 0 0 013.2222-6.4732-1.1472-0.694213.2222QC'd by CBC
Inactive0-6.754.95490.62345.5-2.856340 0 0 1-0.8656-1.96369.1142.2001-0.8656QC'd by CBC
Activator3.1623120.58050Partial curve; high efficacy; poor fit-5.52.58841125.84165.26112.30 0 0 1-13.87585.026113.541121.9395-13.8758QC'd by CBC
Inactive0-5.054.0950.99539.916310.540 0 0 039.90711.81019.210332.148439.907QC'd by CBC
Inactive0-6.754.95490.68855.5-14.272340 0 0 0-1.4364-12.310313.15054.6329-1.4364QC'd by CBC
Inactive0-6.84.95490.48777-4.29940 0 0 012.0135-2.33258.02360.561112.0135QC'd by CBC
Activator14.125456.99660Partial curve; partial efficacy; poor fit-4.851.55790.997555.2294-1.76712.40 0 0 049.6994-2.53631.145221.508449.6994QC'd by CBC
Inactive0-6.74.95490.69788.5-0.540 0 0 10.95120.101311.40645.14890.9512QC'd by CBC
Inactive0-6.84.95490.67113-7.754240 0 0 10-4.378520.24456.04850QC'd by CBC
Inactive04-3.0754-7.5861-4.61-0.5732-3.0754QC'd by CBC
Inactive0-4.950.70.969-220.540 0 0 02.43720.237815.432810.70092.437QC'd by CBC
Inactive0-6.84.50450.7622-2-15.31340 0 0 0-4.8971-12.76082.2051-3.2116-4.8971QC'd by CBC
Inactive0-6.054.50450.999713-6.546540 0 0 10-6.28888.282512.94060QC'd by CBC
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: stopgo-p2-SytraCBC-dual-Ren
Protocol: Reagents:
StopGo2A HEK-NPG-Luc cells and other necessary media and controls were provided by Dr. Atkins's lab. Compound PTC124 was used as a control. Dose response was assessed using a 1:2 dilution of control compound, with the top dose of 50uM final concentration. Background signal was normalized to wells treated with DMSO only.

Assay Protocol:
In brief, four microliters (2400 cells/well) of StopGo2A HEK-NPG-Luc cells were plated and incubated overnight at 37C. Twenty-three nanoliters of compounds and control were added to the wells using a 1536 array Kalypsys pintool workstation. After an overnight incubation (at 37C) with compounds / control, 2.5 uL of Dual/Glo Firefly reagent was added. Firefly luciferase signal was obtained using the PerkinElmer ViewLux plate reader after 20min of room temperature incubation. Dual/Glo Renilla Lucifrase reagents were then added followed by additional 20 min room temperature incubation. Finally, the renilla luciferase signal was obtained using the PerkinElmer ViewLux reader.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00460 uMActivity at 0.023 uMActivity at 0.046 uMActivity at 0.092 uMActivity at 0.115 uMActivity at 0.230 uMActivity at 0.460 uMActivity at 0.911 uMActivity at 1.057 uMActivity at 1.771 uMActivity at 2.301 uMActivity at 4.634 uMActivity at 5.773 uMActivity at 11.50 uMActivity at 16.40 uMActivity at 23.82 uMActivity at 35.99 uMActivity at 57.50 uMActivity at 114.4 uMActivity at 129.1 uMActivity at 273.4 uMActivity at 288.0 uMCompound QC
Activator15.848972.76670Partial curve; partial efficacy; poor fit-4.810.995671.5604-1.20632.40 0 0 056.9219-2.70325.718429.072156.9219QC'd by CBC
Inactive0-5.652.72020.876-3.076-11.137840 0 0 0-4.8556-10.9482-10.07-0.8967-4.8556QC'd by CBC
Activator14.1254116.35980Partial curve; high efficacy; poor fit-4.852.25260.9976114.9836-1.37612.30 0 0 0110.7742-4.01652.526342.9951110.7742QC'd by CBC
Inactive0-4.354.95490.62039-2.125740 0 0 06.649-3.82222.8199-4.68816.649QC'd by CBC
Activator22.387269.80210Partial curve; partial efficacy-4.651.75290.99966.6142-3.18792.20 0 0 055.5041-3.9302-1.545313.513455.5041QC'd by CBC
Inactive04-10.8628-6.0946-6.3923-2.7723-10.8628QC'd by CBC
Activator3.162346.56160Complete curve; partial efficacy-5.51140.0835-6.47811.20 0 0 037.587-4.78416.055430.206537.587QC'd by CBC
Inactive04-5.1322-4.7917-1.3649-10.6528-5.1322QC'd by CBC
Inactive0-4.44.44950.7339130.999240 0 0 011.2209-2.50075.02590.301511.2209QC'd by CBC
Inactive0411.75236.54273.70753.760211.7523QC'd by CBC
Inactive04-13.953-10.1902-10-18.4577-13.953QC'd by CBC
Inactive04-4.5083-2.06295.4547-1.4612-4.5083QC'd by CBC
Inactive04-7.5306-15.4441-6.4413-15.0974-7.5306QC'd by CBC
Inactive0-4.652.25260.9477-26.3385-15.893440 0 0 0-25.2821-17.3753-14.9112-17.8522-25.2821QC'd by CBC
Inactive04-12.6647-11.4457-10.7961-20.5075-12.6647QC'd by CBC
Inactive0-5.14.95490.594-16.1597-5.606740 0 0 1-3.9011-10.3012-3.0056-14.7164-3.9011QC'd by CBC
Inactive0-5.154.95490.9234-15.5602-3.948840 0 0 1-5.8836-5.9172-2.4573-14.6335-5.8836QC'd by CBC
Inactive0-4.354.44950.7251-13.3612-240 0 0 0-10.7177-1.1966-5.59780.8791-10.7177QC'd by CBC
Inactive0-5.74.50450.80751.010810.540 0 0 04.435110.69059.7726-1.65774.4351QC'd by CBC
Activator35.481330.78070Partial curve; partial efficacy; poor fit-4.451.47810.970347.280716.52.40 0 0 037.296914.420618.816221.266337.2969QC'd by CBC